Could herbal pills cut eye injections for wet AMD? new trial launches

NCT ID NCT07269769

Not yet recruiting Disease control Sponsor: Tasly Pharmaceutical Group Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding Sanhuang Jingshiming Pills (a traditional Chinese herbal medicine) to standard ranibizumab injections can reduce the number of injections needed for wet age-related macular degeneration. About 450 adults aged 50-85 with active wet AMD will receive either the herbal pills or a placebo, plus one initial injection. The main goal is to see if the pills help control the disease with fewer injections over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sanhuang Jingshiming Pills (herbal pills) plus ranibizumab injections
What this could lead to: If successful, this combination could reduce the number of eye injections needed for wet age-related macular degeneration, easing treatment burden.
What could go wrong: This is an early-stage trial with 450 participants, and the herbal pill's benefits are unproven. Results may not show a clear advantage over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMD

Contacts and locations

Locations

Beijing Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.